Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 13/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23498518 | 0.82 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL23498669 | 0.79 | ADORA2A (0.50) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21567217 | 0.75 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL20402660 | 0.73 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL3774097 | 0.73 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL11319172 | 0.72 | PDE7A (0.49) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20119693 | 0.71 | KCNH3 (0.40) | JAK2IGF1RPIM1SRCCSNK2A2 | |
| SCHEMBL20119640 | 0.71 | KCNH3 (0.40) | JAK2IGF1RPIM1SRCCSNK2A2 | |
| SCHEMBL23498540 | 0.71 | SMN1; SMN2 (0.52) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL4208839 | 0.71 | PDE4A (0.41) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374602-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. | 2024-11-14 | — | — | US | claimed |
| CN-118401243-A | Methods of treating neurodegenerative diseases | PTC医疗公司 | 2024-07-26 | — | — | CN | claimed |
| EP-4398988-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| US-20240043444-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | claimed |
| EP-4288059-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2023039370-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | claimed |
| EP-4072677-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC Therapeutics, Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| CN-115209955-A | Compounds for the treatment of familial autonomic nerve dysfunction | PTC医疗公司 | 2022-10-18 | — | — | CN | claimed |
| WO-2022169868-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS INC. (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2021118929-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | claimed |
| US-20240374602-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240043444-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | SNRPB2, SYNCRIP, HNRNPUL2 | ADORA2A 1365/4885ADORA2B 760/4885PDE4A 111/4885 |
| US-20240043444-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, ATXN10, ATXN2L | ADORA2A 419/4885ADORA2B 314/4885PDE4A 176/4885 |
| US-20240374602-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | MAPT, MAP1B, MAP2 | ADORA2A 2638/4885ADORA2B 2183/4885PDE4A 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.